Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452072 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
A Phase 2 study of Wound Heal and Surgical Wound, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT03452072: Completed Phase 2 study of Wound Heal and Surgical Wound, sponsored by Brigham and Women's Hospital.
NCT03452072 is a Phase 2 study of Wound Heal and Surgical Wound that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 88 participants, below the 116-participant average among 23 other Wound Heal trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03452072, a Phase 2 study of Wound Heal and Surgical Wound, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 114 patients who have their skin cancer surgically removed resulting in open surgical wounds less or equal to 1.5 cm. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in open surgical wounds less or equal to 1.5 cm.
Primary Outcome
Evaluating the difference in wound re-epithelialization at 30 days after surgery between the groups. Re-epithelialization (yes vs. no) will be evaluated by 2 independent investigators.
Conditions Studied
Interventions
- DRUG 0.25% Timolol gel with paraffin gauze dressings
- OTHER Vaseline dressing
Study Locations (1)
Massachusetts
- Mohs and Dermatologic Surgery Center, Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 2 |
What the finished NCT03452072 record still lists
NCT03452072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 116-participant average among 23 other Wound Heal trials with a reported enrollment target (24% lower).
The record links to 4 conditions, with Wound Heal appearing as the primary indexed condition, and to 2 interventions - of which 0.25% Timolol gel with paraffin gauze dressings is the first listed.
NCT03452072 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03452072 about?
NCT03452072 is a clinical study titled "Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds". The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 114 patients who have their skin cancer surgically removed resulting in open surgical wounds less or equal to 1.5 cm. The objective of t...
What is the current status of trial NCT03452072?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2018-08-20. Estimated completion is 2021-06-30.
What conditions does trial NCT03452072 study?
This clinical trial studies the following conditions: Wound Heal, Surgical Wound, Wound of Skin, Wound Open.
What interventions are being tested in trial NCT03452072?
The interventions under investigation include: 0.25% Timolol gel with paraffin gauze dressings (DRUG), Vaseline dressing (OTHER).
Who is sponsoring clinical trial NCT03452072?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03452072 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound Heal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03452072's enrollment target sits among peer trials
88 11th of 23 higher than 13 of 23 other Wound Heal trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wound Heal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
4-aminopyridine for Skin Wound Healing
RECRUITING · Phase 2
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
COMPLETED · Phase 2
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Dermabrasion in Mohs: Split-Scar Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI